Annals of Thoracic Medicine
REVIEW ARTICLE
Year
: 2010  |  Volume : 5  |  Issue : 1  |  Page : 5--9

Portopulmonary hypertension


Sarfraz Saleemi 
 King Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia

Correspondence Address:
Sarfraz Saleemi
P O Box 3354, King Specialist Hospital and Research Center, Riyadh 11211
Saudi Arabia

Portopulmoanry hypertension (POPH) is a form of pulmonary arterial hypertension (PAH) associated with portal hypertension with or without underlying chronic liver disease. POPH is increasingly recognized and recent evidence suggests that it is one of the leading causes of PAH. The pathophysiology of POPH is poorly understood although the pathological changes in pulmonary vasculature in advanced POPH are similar to those seen in idiopathic pulmonary hypertension. The prognosis in patients with liver disease who also suffer from significant POPH is considered to be poor. Higher degree of pulmonary artery pressure (PAP) may preclude a patient from liver transplant as mortality in these patients is high. The treatment with vasodilator therapy has shown to improve both hemodynamics and clinical outcome in POPH in retrospective studies and in some case series. The aim of medical management is to bring PAP <35 mmHg that may make a patient with POPH and advanced liver disease eligible for liver transplant, which otherwise would have been denied because of high PAP.


How to cite this article:
Saleemi S. Portopulmonary hypertension.Ann Thorac Med 2010;5:5-9


How to cite this URL:
Saleemi S. Portopulmonary hypertension. Ann Thorac Med [serial online] 2010 [cited 2020 Apr 1 ];5:5-9
Available from: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2010;volume=5;issue=1;spage=5;epage=9;aulast=Saleemi;type=0